TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to fulfill oxycodone prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in total white blood cells, neutrophils, and lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in EORTC QLQ-C30 and EORTC-QLQ-CX24 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in lymphocyte surface markers percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lp(a) lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical hemodynamic disturbances defined by arterial hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood disorders evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of ketamine in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily dose requirements of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HBV DNA content in liver biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemoreflex control of MSNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complete and Partial Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of bitter taste 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of bitter taste 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One Year Relapse-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Cure of prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2HG response to IDH305
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility measure per participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total feasibility measure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility measure/Assess loss to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in radiodensitometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric cancer prevention
Endpoint domain: Mortality/survival
Primary endpoint: Colorectal cancer prevention
Endpoint domain: Mortality/survival
Primary endpoint: Apnea Hypopnea Index (AHI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Participants With Laboratory Values Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Electrocardiogram (ECG) Related Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Vital Signs Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Body Weight Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of completed injections at month 6
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: TB treatment success rates
Endpoint domain: Mortality/survival
Primary endpoint: Lost to follow-up among adult drug-sensitive tuberculosis patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of life of TB patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pattern of abstinence from alcohol during intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-cardiac shock frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of anti-tachycardia pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Production of cardiomyocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence-free interval
Endpoint domain: Mortality/survival
Primary endpoint: mean lower leg growth rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capsaicin-Induced Dermal Blood Flow (DBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-T])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of stimulated C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Durability of humoral and cellular immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patient-visits Prescribed an Antimicrobial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Levels of salivary biomarkers (GFAP, S100B, NSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent sitting
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time spent standing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time spent moving
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Percentage Goal Volume Delivered Prior to Development of Intolerance for ITT Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Percentage Goal Volume Delivered Prior to Development of Intolerance for PP Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of change in fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infarct size (% LV mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in myocardial perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biventricular diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Seroprotection Against Tetanus and Diphtheria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Pertussis Geometric Mean Concentrations Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Swallow Response Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Candidate Physical Ability Test Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart to calibration ratios (HCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Partial weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in FVC in % of predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lipoprotein metabolite content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activation of PPAR-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjective and Objective Binge Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Symptom Questionnaire for Neurogenic Bladder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Urine white blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Urine Nitrite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression free survival of NaI-IRI with S1
Endpoint domain: Mortality/survival
Primary endpoint: AUC (Area Under Curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF-I (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IGFBP-1 (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IGFBP-2 (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IGFBP-3 (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Growth Hormone (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Healthy Eating Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-Induced Alcohol Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Learning and Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hemolysis level at 42 days of storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute red cell volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serious complications from intraosseous access
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under Curve of Serial Cardiac Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in objective measure of tinnitus loudness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective handicap rating of tinnitus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum oxygen uptake (VO2 peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in half-time hemoglobin re-oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The Lille Apathy Rating Scale (LARS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spielberger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Independence Measurement-Level (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Correction of scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of suicidal poisoning cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment Success for Treated Bleeding Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Growth Factors and Cytokines Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of hospital acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Effectiveness - MDS/AML/ICUS Cohorts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Effectiveness - MF Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment effectiveness - LTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of self-reported periodontal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest NT-proBNP-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety assessment by Laboratory investigations
Endpoint domain: Adverse events/effects
Primary endpoint: Wechsler Preschool and Primary Scale of Intelligence-IV score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Worst Grade of Adverse Events Experienced (Unrelated to Relatedness to Study Therapy)
Endpoint domain: Adverse events/effects
Primary endpoint: Worst Grade of Adverse Events Experienced (at Least Probably Related to Treatment)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-reported symptoms of vaginal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent superficial vaginal epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the pH of vaginal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage active minutes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Would Recommend the LNG-IUS to a Friend at 6-months Postpartum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Enrolled and Were Able to Have a Successful LNG-IUS Insertion in the 2 Week (Day 14-20) Postpartum Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Actigraph-measured sleep (increased total sleep time)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Compliance with glucose measurement frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Functional and morphological properties of arterial wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of Lp (a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neointimal hyperplasia volume obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Submacular choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical tumor recurrence or progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Kidney transplant outcome
Endpoint domain: Mortality/survival
Primary endpoint: EEG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of cardiomyopathies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity and specificity for distinguishing orbital tumors from orbital pseudotumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival and proliferation of leukemia samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-proliferative or toxic effects of chemotherapeutic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects of novel anticancer drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point-prevalence tobacco abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in average student water consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression Levels of Beta-catenin mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression Levels of Beta-catenin Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometritis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with favorable treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of hemodialysis catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With CDP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in longest diameter of index lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone Resorption Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Nasal persistence of lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease severity correlation with baseline characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease severity correlation with blood biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic susceptibility to severe disease presentations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional anisotropy (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non pre-existing Immune System Disorders (Grade III-IV)
Endpoint domain: Adverse events/effects
Primary endpoint: De novo acute GvHD > Gr II or increase of pre-existing GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of graft rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Who Were Discharged Pain Free That Have a Recurrence of Headache Within 48 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients With Recurrent Headache Within 48 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Accurate Understanding of Chemotherapy Benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic performance of CXR to detect lung recruitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinically relevant delayed bleeding rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Vildagliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Vildagliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: gingival recession width (GRW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of NLFs With Treatment Success at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D/ultrasound imaging of the breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued Study Drug Due To An AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Solicited Adverse Events (AEs) Within 30 Minutes After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any Solicited Local AEs From Day 1 to Day 7 After Each Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: neutralizing antibody seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum 25-hydroxyvitamin D response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24,25(OH)2D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: net score of Iowa Gambling Task Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Grade 3/4 Events of Rash Irrespective of Causality
Endpoint domain: Adverse events/effects
Primary endpoint: Upper limb motor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased sedation and pain requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of BMS-599626
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biologically active doses of BMS-599626
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recommended phase 2 dose of BMS-599626
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: patients' intent to undergo screening for prostate cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of subjects who tolerated a single highest dose of at least 1000 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurotrophins composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes